Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily C Zabor

Showing results (141-150 of 167) with videos related to

Pageof 17
Sort By:
Journal of the National Cancer Institute|November 29, 2013
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinomaA Ari Hakimi, Helena Furberg, Emily C Zabor, et al.
Leukemia & Lymphoma|April 9, 2025
Impact of <i>TP53</i> mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary centerMeera Patel, Emily C Zabor, Ahmed Mohamed, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 11, 2025
Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary CenterAhmed Mohamed, Emily C Zabor, Meera Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2026
The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Anti-Tumor Surveillance ActivationBridget Adcock, Moaath K Mustafa Ali, Emily C Zabor, et al.
Lung Cancer (Amsterdam, Netherlands)|November 20, 2025
Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort studyHeya Batah, Emily C Zabor, Bridget Adcock, et al.
Cancer|June 17, 2022
A multi-institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for T1-2N1 breast cancerSarah M C Sittenfeld, Emily C Zabor, Sarah N Hamilton, et al.
Cancer|August 2, 2016
Genomic characterization of response to chemoradiation in urothelial bladder cancerNeil B Desai, Sasinya N Scott, Emily C Zabor, et al.
European Urology|August 6, 2014
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladderPhilip H Kim, Eugene K Cha, John P Sfakianos, et al.
European Urology Focus|September 28, 2017
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell CarcinomaJozefina Casuscelli, Maria F Becerra, Brandon J Manley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancerGopa Iyer, Hikmat Al-Ahmadie, Nikolaus Schultz, et al.
Pageof 17

Showing results (141-150 of 167) with videos related to

Sort By:
Pageof 17
Journal of the National Cancer Institute|November 29, 2013
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinomaA Ari Hakimi, Helena Furberg, Emily C Zabor, et al.
Leukemia & Lymphoma|April 9, 2025
Impact of <i>TP53</i> mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary centerMeera Patel, Emily C Zabor, Ahmed Mohamed, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 11, 2025
Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary CenterAhmed Mohamed, Emily C Zabor, Meera Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2026
The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Anti-Tumor Surveillance ActivationBridget Adcock, Moaath K Mustafa Ali, Emily C Zabor, et al.
Lung Cancer (Amsterdam, Netherlands)|November 20, 2025
Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort studyHeya Batah, Emily C Zabor, Bridget Adcock, et al.
Cancer|June 17, 2022
A multi-institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for T1-2N1 breast cancerSarah M C Sittenfeld, Emily C Zabor, Sarah N Hamilton, et al.
Cancer|August 2, 2016
Genomic characterization of response to chemoradiation in urothelial bladder cancerNeil B Desai, Sasinya N Scott, Emily C Zabor, et al.
European Urology|August 6, 2014
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladderPhilip H Kim, Eugene K Cha, John P Sfakianos, et al.
European Urology Focus|September 28, 2017
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell CarcinomaJozefina Casuscelli, Maria F Becerra, Brandon J Manley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancerGopa Iyer, Hikmat Al-Ahmadie, Nikolaus Schultz, et al.
Pageof 17